Systemic therapy for non-serous ovarian carcinoma

Chávarri‐Guerra, Yanin; González-Ochoa, Eduardo; Mora-Molina, Hector de la; Soto‐Pérez‐de‐Celis, Enrique

doi:10.21037/cco-20-36

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the patients are in the early stage. But most of the patients are less sensitive to traditional platinum-based chemotherapy compared with high-grade serous tumors [15] . Since non-serous EOC patients are mostly found in the early stage, the prognosis are better.…”

Section: Discussionmentioning

confidence: 99%

A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center

Zheng,

Chen,

Huang

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center

Zheng,

Chen,

Huang

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study

Heras,

Azcona,

Arencibia

et al. 2024

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveTo assess the safety of fertility‐sparing treatments for early‐stage ovarian cancer in women younger than 40 years old.MethodsWe performed a retrospective multicenter study including women aged 18–40 years diagnosed with early‐stage (FIGO I–II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced stages (FIGO III–IV). All perioperative characteristics and follow‐up data were collected and analyzed. Standard staging surgery (SSS) was compared with fertility‐sparing surgery (FSS) in terms of oncological outcomes.ResultsIn all, 366 women were included; 327 (89.3%) were stage I. Among all patients, 216 (59%) underwent SSS and 150 (41%) FSS. Up to 208 (56.8%) patients did not have children, but only 12 (3.2%) had oocyte preservation before treatment. Patients in the FSS group compared with the SSS group showed a non‐significant difference in recurrences (8% vs. 9.3%, respectively; P < 0.711) and deaths (1.3% vs. 4.8%, respectively; P = 0.211) during the follow‐up. No significant differences were found between epithelial and non‐epithelial ovarian cancer both in recurrences (7.1% vs. 8.8%, respectively; P = 0.771) and in deaths (1.4% vs. 1.3%, respectively; P = 1) among patients who underwent FSS.ConclusionFSS seems a safe option for treatment of early‐stage ovarian cancer in patients who want to preserve fertility, either for epithelial and non‐epithelial histology.

show abstract

DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma

Arend¹,

Dholakia²,

Castro³

et al. 2023

Gynecologic Oncology

View full text Add to dashboard Cite

Systemic therapy for non-serous ovarian carcinoma

Cited by 3 publications

References 0 publications

A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center

A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center

Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study

DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma

Contact Info

Product

Resources

About